** Brokerage Stifel raises PT on drugmaker Alnylam Pharmaceuticals' ALNY.O to $345 from $300 following expanded U.S. approval for its heart disease drug
** The new PT represents a 28.5% upside to the stock's last close
** Brokerage believes ALNY's drug Amvuttra will be a "go-to therapy" for patients with heart disease condition who progress on a stabilizer
** Amvuttra, a quarterly injection, was cleared to treat ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart and potentially causing organ to fail
** Stifel says physician feedback on the drug has been broadly favorable
** Twenty four of 31 brokerages rate the stock "buy" or higher, 7 "hold"; their median PT is $316.71, according to data compiled by LSEG
** As of last close, ALNY has risen 80% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.